Q-omics provides the consensus-scored MRPL22 profile across patient tissues and cancer cell-line models. MRPL22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MRPL22 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MRPL22 protein abundance shows 26,190 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where MRPL22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL22 survival associations across molecular data types. MRPL22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL22 RNA expression–survival associations across cancer types. High MRPL22 expression shows unfavorable associations in HNSC, UVM, LUAD, UCS, KICH and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for MRPL22 RNA expression.
This table summarizes MRPL22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL22 shows higher tumor expression in KIRC, COAD, LIHC, LUAD, HNSC and UCEC. The KIRC box plot shows higher MRPL22 RNA expression in tumor versus normal tissue (log2 FC = +0.668, t-test p < 0.001).
This table shows molecular features associated with MRPL22 in patient tissues and cancer cell lines. In patient samples, MRPL22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
